Authors
Latest:
Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MMThe panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
Latest:
The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint InhibitorsBen Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.
Latest:
Addressing Resistance to Targeted Therapies in Metastatic Colorectal CancerInvestigators discuss the use of targeted therapies to treat metastatic colorectal cancer.
Latest:
Advancing Pancreatic Cancer Care Through Intraoperative Radiation TherapyExperts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.
Latest:
Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRCThe panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
Latest:
Face-Off: Award Presentation CeremonyFollowing a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Latest:
Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future OutlookUntil 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Emergency Fertility Preservation in a Young Woman With Non-Hodgkin LymphomaA nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell CarcinomaIn this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
Latest:
Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple MyelomaPanelists discuss how the use of CAR T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma could potentially improve long-term outcomes, considering factors such as patient selection, optimal timing, and the impact on subsequent treatment options.
Latest:
Unmet Needs and Future Perspectives in the Treatment of CLLThe panel shares some final thoughts on unmet needs and the future of CLL treatment.
Latest:
Highlighted Data Review of CAR-T in Early R/R MMPanelists discuss how early-line chimeric antigen receptor T-cell therapy studies, including recent data from trials of cilta-cel (Popat et al) and ide-cel (Ailawadhi et al), are showing promising results in patients with relapsed/refractory multiple myeloma, suggesting potential benefits of moving these treatments into earlier therapeutic settings.
Latest:
Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid CancerEric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Latest:
Spinal ATRT and Radiotherapy Case Report in an Adult ManA rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.
Latest:
Frontline Forum: Real-World Practice in Newly Diagnosed Multiple MyelomaExperts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
